• 1. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 2. Fe3O4/FeS2 heterostructures enable efficient oxygen evolution reaction?
  Xingqun Zheng,Lele Song,Xin Feng,Li Li,Zidong Wei J. Mater. Chem. A, 2020,8, 14145-14151
• 3. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 4. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 5. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Medium-chain fatty acids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty acids and conjugates Medium-chain fatty acids

Comprehensive Overview of Boc-L-beta-Homoleucine (CAS No. 132549-43-0): Properties, Applications, and Industry Insights

In the rapidly evolving field of peptide synthesis and pharmaceutical research, Boc-L-beta-Homoleucine (CAS No. 132549-43-0) has emerged as a critical building block for advanced drug development. This non-natural amino acid derivative is widely recognized for its unique structural properties, which enable precise modifications in peptide chains. With the growing demand for custom peptide synthesis and bioconjugation, this compound has garnered significant attention from researchers and manufacturers alike.

The tert-butoxycarbonyl (Boc) protecting group in Boc-L-beta-Homoleucine ensures stability during complex synthetic processes, making it indispensable for solid-phase peptide synthesis (SPPS). Its CAS No. 132549-43-0 serves as a unique identifier in regulatory documentation and procurement databases. Recent trends in peptide-based therapeutics highlight the compound's relevance, particularly in developing targeted drug delivery systems and enzyme inhibitors.

One of the most frequently searched questions in scientific forums is: "What are the advantages of using Boc-L-beta-Homoleucine over other amino acid derivatives?" The answer lies in its enhanced steric flexibility and resistance to racemization, which are crucial for maintaining chiral purity in final products. Additionally, its compatibility with Fmoc chemistry allows seamless integration into diverse synthesis protocols.

From an industrial perspective, Boc-L-beta-Homoleucine is pivotal in producing peptide mimetics and macrocyclic compounds, addressing key challenges in bioavailability optimization. The compound's role in structure-activity relationship (SAR) studies further underscores its value in rational drug design. As the pharmaceutical industry shifts toward personalized medicine, demand for specialized amino acids like this is projected to rise exponentially.

Quality control parameters for CAS No. 132549-43-0 typically include HPLC purity (>98%), optical rotation verification, and rigorous residual solvent analysis. These specifications align with ICH guidelines and GMP standards, ensuring compliance for preclinical and clinical applications. Researchers often inquire about storage conditions for Boc-protected amino acids – this compound requires desiccated storage at -20°C to prevent Boc group cleavage.

Emerging applications in biomaterials engineering have expanded the utility of Boc-L-beta-Homoleucine beyond traditional pharmaceuticals. Its incorporation into self-assembling peptides demonstrates potential for tissue scaffolding and wound healing matrices. This interdisciplinary relevance makes it a frequent subject in grant proposals and patent applications related to regenerative medicine.

The synthesis of Boc-L-beta-Homoleucine involves sophisticated asymmetric catalysis techniques to ensure high enantiomeric excess. Process chemists emphasize the importance of green chemistry principles in its production, minimizing hazardous byproducts. Recent publications have explored continuous flow synthesis methods to enhance scalability – a response to industry demands for cost-effective peptide intermediates.

For analytical characterization, techniques like LC-MS, NMR spectroscopy, and chiral HPLC are routinely employed. The compound's mass spectrometry fragmentation pattern serves as a fingerprint for identity confirmation, while 2D-NMR studies elucidate its conformational preferences. These analytical workflows address another common search query: "How to validate the structure of Boc-L-beta-Homoleucine?"

Market analysis indicates steady growth for protected amino acid suppliers, driven by expanding contract research organizations (CROs) and academic research programs. Strategic partnerships between fine chemical manufacturers and biotech startups are accelerating innovation in this niche. The compound's pricing reflects its high-purity niche chemical status, with bulk procurement offering economies of scale.

Future research directions may explore Boc-L-beta-Homoleucine's potential in peptide-drug conjugates (PDCs), particularly for oncology targets. Its beta-amino acid backbone provides metabolic stability advantages over conventional peptides – a property increasingly valued in next-generation biologics. As regulatory agencies refine guidelines for peptide-based NCEs, standardized protocols for derivatives like CAS No. 132549-43-0 will become increasingly important.

• 218608-82-3(Boc-l-β-homoisoleucine)
• 497106-86-2(Hexanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-4-methyl-,(3S,4R)-)
• 187610-56-6(N-Boc-2-(1-aminocyclohexyl) acetic Acid)
• 1188263-93-5(2-(1-amino-4-{(tert-butoxy)carbonylamino}cyclohexyl)acetic acid)
• 146398-18-7((3R)-3-(tert-butoxycarbonylamino)-5-methyl-hexanoic acid)
• 138165-75-0(3-((tert-Butoxycarbonyl)amino)-5-methylhexanoic acid)
• 886503-06-6(3-(tert-butoxycarbonylamino)-4-cyclohexyl-butanoic acid)
• 776330-59-7(Heptanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-4-methyl-)
• 210711-44-7((3R)-4-cyclohexyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid)
• 776330-61-1(Tridecanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-4-methyl-)